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Drosophila peptidoglycan recognition protein LC (PGRP-LC), a
transmembrane protein required for the response to bacterial
infection, acts at the top of a cytoplasmic signaling cascade that
requires the death-domain protein Imd and an IB kinase to
activate Relish, an NF-B familymember. It is not clear howbinding
of peptidoglycan to the extracellular domain of PGRP-LC activates
intracellular signaling because its cytoplasmic domain has no
homology to characterized proteins. Here, we demonstrate that
PGRP-LC binds Imd and that its cytoplasmic domain is critical for its
activity, suggesting that PGRP-LC acts as a signal-transducing
receptor. The PGRP-LC cytoplasmic domain is also essential for the
formation of dimers, and results suggest that dimerization may be
required for receptor activation. The PGRP-LC cytoplasmic domain
canmediate formation of heterodimers between different PGRP-LC
isoforms, thereby potentially expanding the diversity of ligands
that can be recognized by the receptor.
Imd  innate immunity  NF-B  Relish
Pattern-recognition receptors (PRRs) are host innate immunereceptors that recognize microbial-specific molecules called
pathogen-associated molecular patterns (PAMPs) and activate
host defense responses (1). The best-characterized PRRs are the
mammalian Toll-like receptor (TLR) family, in which each TLR
appears to recognize and mediate the response to a different
PAMP. The founding member of the TLR gene family is
Drosophila Toll, which is required for the response of Drosophila
to fungal and Gram-positive bacterial infections (2–4). In con-
trast to the mammalian TLRs, Toll does not appear to act as a
PRR; pathogen recognition leads to activation of a protease
cascade that produces a ligand for Toll (5, 6).
The PRRs that have been identified in Drosophila belong to a
different protein family, the peptidoglycan-recognition proteins
(PGRPs), which bind bacterial peptidoglycan. The first PGRP to
be characterized was a silkworm (Bombyx mori) protein that is
required for one branch of the insect immune response: the
phenoloxidase cascade that leads to localized melanization at
infection sites (7, 8). Subsequently, genes encoding PGRPs of
related structure were identified in other animals, from Dro-
sophila to humans (9–11). These proteins all include a pepti-
doglycan-recognition domain of 165 aa that has structural
similarity to the peptidoglycan-binding region of lysozyme (12).
The essential role of PGRPs in the Drosophila immune
response was revealed by characterization of immunodeficient
mutants. Two genes that encode PGRPs, PGRP-SA and PGRP-
LC, are required in two different branches of the immune
response. PGRP-SA is a soluble protein that is present in the
hemolymph (the blood plasma equivalent) and is required for
the normal response to Gram-positive bacteria (13). Binding of
Gram-positive type peptidoglycan to PGRP-SA (10), together
with Gram-negative binding protein 1 (GNBP1) (14), activates
the protease cascade that produces the mature ligand for Toll (6,
15). Toll activation promotes nuclear translocation of the Rel
NF-B proteins Dif and Dorsal, which induce expression of the
antimicrobial peptide Drosomycin. PGRP-LC is a transmem-
brane protein that is required for the response to bacterial
infection mediated by the Imd-Relish signaling pathway (16–18).
PGRP-LC acts genetically upstream of Imd to promote process-
ing and nuclear localization of Relish, the third Drosophila
RelNF-B protein. Activated Relish promotes transcription of
genes encoding a distinct set of antibacterial peptides, including
Diptericin (Dpt) and CecropinA1 (CecA1) (16, 19). The three
major isoforms of the PGRP-LC gene (PGRP-LCa , PGRP-LCx,
and PGRP-LCy) are generated by alternative splicing (10, 16,
20). These isoforms share common cytoplasmic and transmem-
brane domains, but the extracellular PGRP domains are only
39% identical, and they appear to be activated by different forms
of peptidoglycan (21).
Despite the genetically defined function of PGRP-LC, the
cytoplasmic domain of PGRP-LC has no sequence homology to
characterized proteins and its biochemical function is unknown.
In this article, we express full-length and truncated forms of
PGRP-LC and Imd to define the functions and interactions of
protein domains. Our studies demonstrate that activated
PGRP-LC is present as multimeric complexes, that the cyto-
plasmic domain of the protein of PGRP-LC is necessary and
sufficient to activate downstream signaling, and that PGRP-LC
binds a previously uncharacterized domain of Imd.
Methods
DNA Constructs. cDNA clones for imd (GH20785) and PGRP-LCa
(LP06704) were purchased from Research Genetics (Huntsville,
AL). PGRP-LCx cDNA is described in ref. 16. All imd constructs
were subcloned into EcoRI–NotI sites of pMTV5-HisA vector
(Invitrogen) to generate V5 and 6 His C-terminally tagged
proteins. The following primer sets were used in PCR amplifi-
cation of different imd constructs: primers 1 and 5 for the
full-length Imd (see the primer list below); primer 2 and 5 for
Imd1–135; primers 1 and 3 for Imd136–273; and primers 1 and 4
for Imd173–273. For c-Myc-tagged PGRP-LCa and LCx, con-
structs were subcloned intoEcoRI–PmeI sites of pMTV5-HisA,
which resulted in the deletion of vector-originated V5 and 6
His tags. The following primer sets were used for C-terminal
c-Myc tagging: primers 6 and 7 for PGRP-LCa; and primers 6
and 8 for PGRP-LCx. For V5 6 His-tagged full-length and
deletion constructs for PGRP-LCa and PGRP-LCx, constructs
were subcloned into EcoRI–NotI sites of pMTV5-HisA. The
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following sets of primers were used for PCR amplification:
primers 6 and 9 for PGRP-LCa; primers 6 and 10 for PGRP-LCx;
primers 11 and 10 for PGRP-LCx1–144; primers 12 and 10 for
PGRP-LCx1–263; primers 6 and 13 for PGRP-LCx333–500; and
primers 6 and 14 for PGRP-LCx394–500. Primer 1 (forward),
5-CCGAATTCATGTCAAAGCTCAGGAACCTGT-3;
primer 2 (forward), 5-GGTTACGAATTCATGCGAAA-
GGGTAGCACCAGTACCG-3; primer 3 (reverse), 5-GC-
TAATGCGGCCGCGGCGAGCTGCAGGCGCTCAAGT-
TT-3; primer 4 (reverse), 5-GCTAATGCGGCCGCGG-
TTGTGACTGCATCATGGCCACA-3; primer 5 (reverse), 5-
TTGCGGCCGCGGGCTGTTTGTCTTGCGCTTCTCC-3;
primer 6 (forward), 5-CCGAATTCATGCCTTTTAGCAAT-
GAAACGG-3; primer 7 (reverse), 5-GGCCGGGT-
TTAAACTTATTACAAGTCCTCTTCAGAAATGAGCTT-
TTGCTCCGACCAATGAGTCCAGTTGGC-3; primer 8
(reverse), 5-GGCCGGGTTTAAACTTATTACAAGTC-
CTCTTCAGAAATGAGCTTTTGCTCGATTTCGTGT-
GACCAGTGCGG-3; primer 9 (reverse), 5-TTGCGGCCGC-
CCCGACCAATGAGTCCAGTTGGCGAAGCTTGC-3;
primer 10 (reverse), 5-TTGCGGCCGCCCGATTTCGTGT-
GACCAGTGCGGCCACTT-3; primer 11 (forward), 5-
CCGAATTCATGAGTTCACACCTGCGCGACCTTAA-3;
primer 12 (forward), 5-CCGAATTCATGGGAAGTGCGC-
CGGGCTCCAAACAC-3; primer 13 (reverse), 5-TTGCG-
GCCGCCCGCTATTATCGATGACATCCAAGT-3; and
primer 14 (reverse), 5-TTGCGGCCGCCCACCCCAGCT-
GTCCATGTGAAACG-3.
S2 Cell Culture and Transfection.Maintenance and transient trans-
fection of Drosophila S2 cells were performed by following the
manufacturer’s suggested protocols with no modification (DES-
Inducible kit, Invitrogen). S2 cells were cultured and passaged
every 4 or 5 days in Schneider’s Drosophila medium supple-
mented with 10% heat-inactivated FBS, 50 unitsml penicillin G,
and 50 gml streptomycin sulfate (Invitrogen). Transient trans-
fection was performed by using the calcium phosphate method
with 20 g of DNA. Induction of genes under the control of the
metallothionein promoter was performed by adding CuSO4 to
the medium at the final concentration of 500 M at 48–72 h or
48–96 h after transfection.
Immune Challenge. Escherichia coli cells were cultured overnight
until OD600 reached 1.5. E. coli bacteria were washed and
resuspended in PBS (pH 7.5) and added to S2 cell culture at an
appropriate concentration (see Fig. 1 legend). S2 cells were
harvested 6 h after incubation. Injections of adult f lies with E.
coli were carried out as described in ref. 22.
Coimmunoprecipitation and Western Blot Analysis. Lysates were
prepared from 10-ml cultures of transiently transfected cells by
adding 1 ml RIPA buffer containing 1 PBS, 1% Igepal CA-630
(Sigma–Aldrich), 0.5% sodium deoxycholate, 0.1% SDS with
phosphatase inhibitor (100 M sodium orthovanadate), and
protease inhibitors (Roche Applied Science). Lysates were pre-
cleared by adding 50 l of 1:1 slurry of protein A–Sepharose in
PBST (PBS, pH 7.51% Triton-X-100) containing 1 mgml
BSA, followed by rocking for 30 min at 4°C and centrifugating
the samples for 5 s at 15,000 g. The resulting supernatants were
transferred to fresh tubes, and 50 l of protein A–Sepharose was
added with 2 g of anti-c-Myc rabbit polyclonal IgG (Research
Diagnostics, Flanders, NJ) or 2 g of anti-V5 mouse monoclonal
IgG (Invitrogen). Samples were then incubated overnight at 4°C
with rocking. Immunoprecipitates were washed with RIPA
buffer four times each for 10 min, separated by 12.5% SDS
PAGE, and transferred to nitrocellulose. Blots were probed with
either the anti-V5 or the anti-c-Myc antibodies (1:2,000 dilution)
overnight.
Northern Blot Analysis for the Induction of Antimicrobial Peptides.
The 5-ml cultures of S2 cells were harvested after protein
expression and immune challenge as described above. RNAs
were prepared by homogenizing the cells in 1 ml of RNA
STAT-60 solution (Tel-Test, Friendswood, TX). Subsequent
RNA purification steps were performed by following the man-
ufacturer’s instructions. Northern blot analyses were performed
as described (22, 23).
Results
The Cytoplasmic Domain of PGRP-LC Is Required for Downstream
Signaling. To study the activities and physical properties of the
PGRP-LC isoforms, we constructed and expressed V5-tagged
and c-Myc-tagged full-length PGRP-LCa and PGRP-LCx in
Drosophila S2 cells (a macrophage-like cell line). The predicted
sizes of PGRP-LCa and PGRP-LCx proteins were 57 and 55 kDa
(16), and each isoform migrated as a cluster of three bands of
66 kD (Fig. 1b, lanes 3 and 4), possibly the result of posttrans-
lational modification.
The antibacterial peptide gene CecropinA1 (CecA1), which is
induced in response to infection of Drosophila larvae or adults,
is also induced by overexpression of PGRP-LCa or PGRP-LCx
in transgenic flies (16, 17). Activation of CecA1 by PGRP-LC
overexpression requires the same downstream gene products
required for the response to bacterial infection. Overexpression
of epitope-tagged full-length PGRP-LCa or PGRP-LCx in S2
cells induced expression ofCecA1 to the same level as incubation
of the cells with E. coli for 6 h (Fig. 1c, lanes 3 and 4 vs. 9 and
Fig. 1. Domains of PGRP-LCx required for antimicrobial peptide gene induction. (a) PGRP-LC deletion constructs. PGRP-LC is a type II transmembrane protein
with a previously uncharacterized N-terminal cytoplasmic domain, a transmembrane domain (TM) and a C-terminal PGRP domain. A V5 epitope was added in
the C terminus of full-length and deletion constructs. (b) Protein expression in transiently transfected S2 cells was confirmed by Western blotting with anti-V5
antibody. (c) Induction of CecA1 was measured on Northern blots with RNA samples prepared from S2 cells expressing the PGRP-LCx deletion constructs. RNAs
were purified from the cells after protein expression and, as shown in lanes 9–16, treatment with E. coli (102-fold dilution of OD600  1.5, 6 h of incubation).
Rp49 was used as a loading control.
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10; Myc-tagged PGRP-LCa and PGRP-LCx-induced CecA1 to
similar levels).
We used the activation of CecA1 expression in S2 cells as an
assay to map the domains of PGRP-LC that are important for
activation of downstream signaling. PGRP-LCx encodes a type II
transmembrane protein with a 293-aa N-terminal cytoplasmic
domain and a 187-aa C-terminal extracellular domain that
includes the peptidoglycan-recognition domain (Fig. 1a). Con-
structs that lacked the N-terminal half of the cytoplasmic region
(PGRP-LC1–144) showed greatly reduced induction of CecA1,
and constructs that lacked 90% of the cytoplasmic region
(PGRP-LC1–263) failed completely to induce CecA1 (Fig. 1c,
lanes 5 and 6). In contrast, overexpression of constructs that
lacked 90% of the extracellular domain, including the entire
peptidoglycan-recognition domain (PGRP-LC333–500), induced
CecA1 expression to levels comparable with that seen with
full-length PGRP-LC (Fig. 1c, lane 7). Thus, the membrane-
tethered cytoplasmic domain, but not the extracellular PGRP
domain, is crucial for activation of the downstream events
that lead to CecA1 induction in response to PGRP-LC
overexpression.
Physical Interactions Between PGRP-LC and Imd, a Putative Adaptor
Protein.The death-domain protein Imd functions at the top of the
genetically defined cytoplasmic signaling cascade required for
the activation of the Relish transcription factor (24–27). Because
epistasis analyses demonstrated that Imd acts downstream of the
transmembrane protein PGRP-LC (17), we tested whether
PGRP-LC and Imd could be components of the same protein
complex. V5-tagged Imd expressed in Drosophila S2 cells mi-
grated as five major bands ranging in size from 20 to 40 kDa (Fig.
2b); based on the migration of truncated forms of the protein
(see below), it is likely that the 40-kD protein represents
full-length Imd (28). Overexpression of epitope-tagged Imd
induced CecA1 expression, as had been observed previously in
both Imd-overexpressing transgenic flies and S2 cells (28). The
Imd protein includes an 80-aa C-terminal death domain and a
173-aa N-terminal region that shows no significant homology to
other proteins (28). We expressed three deletion constructs of
Imd (Fig. 2a) in S2 cells. The constructs deleted the N-terminal
half, the C-terminal half including the death domain, and only
the death domain: Imd1–135, Imd136–273 and Imd173–273. Al-
though each deletion construct produced stable protein, none of
the deleted versions of Imd induced CecA1 expression (Fig. 2c,
lanes 4–6), indicating that both N-terminal and C-terminal
domains are essential in this assay.
To test for physical associations between PGRP-LC and Imd,
we coexpressed epitope-tagged Imd and PGRP-LC isoforms in
S2 cells. As shown in Fig. 3, Imd coprecipitated with either
PGRP-LCa or PGRP-LCx. Similar results were obtained in
reciprocal coimmunoprecipitation assays in which Imd was
immunoprecipitated and PGRP-LC was detected in the precip-
itate (data not shown).
Imd constructs that lacked the C-terminal death domain
(173–273) or the C-terminal half of the protein (136–273) still
coimmunoprecipitated with PGRP-LCx (Fig. 4, lanes 5 and 6).
In contrast, deletion of the N-terminal half of Imd (1–135)
abolished its ability to bind PGRP-LCx, defining the Imd N
terminus as the essential PGRP-LC interaction domain (Fig. 4,
lane 4). Similar results were observed in reciprocal coimmuno-
precipitation assays (data not shown).
Homotypic and Heterotypic Interactions Between PGRP-LC Isoforms.
Many transmembrane receptors, including some TLRs, function
as dimers or oligomers (29–31). To test whether PGRP-LC can
form multimeric complexes, we examined the ability of epitope-
tagged PGRP-LC isoforms to coimmunoprecipitate. As shown
in Fig. 5 (lanes 5 and 6), V5-tagged PGRP-LCa coimmunopre-
cipitated with c-Myc-tagged PGRP-LCa. The same results were
obtained with LCx isoform, indicating that both isoforms are
capable of homotypic interactions. In addition, coexpressed
PGRP-LCa and PGRP-LCx coimmunoprecipitated, indicating
that they are capable of heterotypic interaction (Fig. 5, lane 7).
We tested the deletion constructs to identify the domains
required for the interaction between PGRP-LCx monomers.
Truncated constructs lacking the C-terminal half or 90% of the
Fig. 2. Domains of Imd required for antimicrobial peptide gene induction. (a) Imd deletion constructs. The C-terminal 80-aa death domain (DD) is shown. V5
tag was added in the C terminus of full-length and deletion constructs. (b) Protein expression in transiently transfected S2 cells was confirmed by Western blotting
with anti-V5 antibody. (c) Induction of CecA1was measured on Northern blots. Deletion of the N-terminal half, the C-terminal half including the death domain,
or only the death domain all abolished CecA1 induction.
Fig. 3. Physical interaction of PGRP-LC and Imd. Lysates were prepared from
S2 cells transiently transfected with expression vectors for V5-tagged Imd and
c-Myc-tagged PGRP-LCa or PGRP-LCx (20 g each). Anti-c-Myc antibody was
used to immunoprecipitate PGRP-LC, and anti-V5 antibody was used to detect
Imd on Western blots.
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extracellular domain coimmunoprecipitated with full-length
PGRP-LCx as efficiently as the full-length protein (Fig. 6, lanes
10 and 11). Truncated protein that lacked the membrane-distal
(N-terminal) half of the cytoplasmic domain could interact with
full-length PGRP-LCx as well as the full-length protein (Fig. 6,
lane 8). In contrast, deletion of 90% of the cytoplasmic domain
abolished the interaction, (Fig. 6, lane 9). Similar results were
seen in reciprocal coimmunoprecipitation assays (data not
shown). Thus, the membrane-proximal half of the cytoplasmic
domain is required for the interaction between monomers.
Discussion
The data presented here demonstrate that PGRP-LC is an
essential component of a signal-transducing receptor complex
that presumably binds peptidoglycan PAMPs and initiates the
cellular response to this PAMP. The other PGRP required in a
Drosophila immune response, PGRP-SA, is a small, soluble
protein that circulates in the hemolymph and is required for
activation of a hemolymph protease cascade (13). In contrast,
PGRP-LC is a transmembrane protein that acts as a PRR that
directly couples pathogen recognition to intracellular signaling.
All isoforms of PGRP-LC share a common cytoplasmic
domain that has no similarity to other proteins. Nevertheless, the
deletion analysis presented here defines three functions for the
previously uncharacterized cytoplasmic domain of PGRP-LC.
First, the membrane-proximal half of the PGRP-LC cytoplasmic
domain is required for formation of multimeric receptor com-
plexes. Interactions between PGRP-LC isoforms have been
detected (21), but it was not known which domains mediated
interaction. As noted previously, the ability to form heteromeric
complexes may broaden the spectrum of PAMPs that can be
recognized. Second, PGRP-LC can form a complex with the
cytoplasmic protein Imd. Our experiments demonstrate that the
N-terminal domain of Imd is essential for its interaction with
PGRP-LC, although that interaction need not be direct. Third,
the PGRP-LC cytoplasmic domain is necessary and sufficient for
activation of downstream signaling, as assayed by expression of
CecA1. The results suggest that activation of signaling could
involve the following sequence of events: binding of bacterial
proteoglycan to PGRP-LC induces receptor multimerization
(which can be mimicked by overexpression); and multimeriza-
tion of the receptor activates the protein complex that includes
both PGRP-LC and Imd, ultimately leading to activation of the
IB kinase (Ird5) and Relish activation.
Although PGRP-LC has no homology to TLRs, our data
highlight parallels between the PGRP-LCImd and TLR path-
ways. TLR signaling requires a membrane complex that includes
the TLR and death-domain protein MyD88; similarly, signaling
from PGRP-LC occurs in a complex that includes the death-
domain protein Imd. TLR activity causes activation of an IB
kinase complex that phosphorylates the inhibitor protein IB
(32); similarly, activation of PGRP-LC leads to activation of an
Fig. 4. Identification of the domain of Imd that interacts with PGRP-LC.
Lysates were prepared from cells transiently transfected with expression
vectors for a V5-tagged Imd deletion construct and c-Myc-tagged PGRP-LCx
(20 g each). Anti-c-Myc antibody was used to immunoprecipitate the full-
length PGRP-LCx, and anti-V5 antibody was used to detect Imd on Western
blots. Deletion of the N-terminal half of Imd abolished the interaction,
whereas deletion of the C-terminal half did not prevent interaction, suggest-
ing that the N-terminal part is responsible for the interaction with PGRP-LC.
Fig. 5. Homotypic and heterotypic interactions between PGRP-LCa and
PGRP-LCx. Lysates were prepared from cells transiently transfected with ex-
pression vectors for the two PGRP-LC isoforms tagged with either V5 or c-Myc
(20 g each) and subjected to coimmunoprecipitation.
Fig. 6. Mapping of the region of PGRP-LCx required for homotypic interac-
tions. Lysates derived from cells transiently transfected with expression vec-
tors for a V5-tagged deletion construct and the c-Myc-tagged full-length
PGRP-LCx (20 g each) were prepared and subjected to coimmunoprecipita-
tion. Anti-c-Myc antibody was used to immunoprecipitate the full-length
PGRP-LCx and anti-V5 antibody was used to detect the deletion constructs of
PGRP-LCx by Western blotting. Note that deletion of the extracellular domain
did not significantly affect the interaction, whereas deletion of the cytoplas-
mic domain abolished it (arrows mark IP products in lanes 7, 8, 10, and 11).
Deletion of the distal half of the cytoplasmic domain did not prevent the
interaction (lane 8), suggesting that the proximal half of the cytoplasmic
domain is crucial for the interaction.
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IB kinase complex that phosphorylates the Rel-Ank protein
Relish. The adaptor molecule MyD88 has an N-terminal death
domain and the C-terminal TIR domain (33–37). The MyD88
TIR domain binds the TIR domain of TLR and theMyD88 death
domain binds the death domain of the kinase IRAK, thereby
linking the membrane receptor to downstream events. Although
the cytoplasmic domain of PGRP-LC is not similar to any other
protein, our data suggest that it is required for interaction with
the previously uncharacterized N-terminal domain of Imd. The
C-terminal half (132–273) of Imd contains a death domain and
can interact with another death-domain protein, dFADD (27),
which is required for downstream signaling and could be also a
part of the receptor complex.
In animals, the immune-responsive tissues are the fat body,
blood cells (38, 39), and epidermis (40–43). Although the
interactions described here occur in Schneider cells, a hemocyte
line, it is likely that PGRP-LC and Imd interact in the fat body
and possibly the epidermis as well. Imd and PGRP-LC mutants
have very similar effects on the antimicrobial peptide response
in flies, and most of the antimicrobial peptides are produced in
the fat body. Overexpression of PGRP-LC in the fat body is
sufficient to drive antimicrobial peptide induction, indicating
that the fat-body cells are ready to initiate the signaling upon the
presence of active PGRP-LC (16, 17). The response to septic
wounding that was used to define the phenotypes of both Imd
and PGRP-LC mutants (16–18) can occur in the absence of
blood cells (44). Imd also acts in the epidermis to allow a local
response to septic wounding (42), and it is likely that PGRP-LC
also acts at that site. Although we have provided information
about the biochemical mechanism of action of PGRP-LC, ad-
ditional work will be required to define the diversity of functions
of PGRP-LC in systemic immune responses.
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